Currently, there are 44.27M common shares owned by the public and among those 41.32M shares have been available to trade.
The company’s stock has a 5-day price change of 108.00% and 107.12% over the past three months. TCON shares are trading 122.73% year to date (YTD), with the 12-month market performance down to -72.73% lower. It has a 12-month low price of $0.13 and touched a high of $2.19 over the same period. TCON has an average intraday trading volume of 1.93 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 98.92%, 108.76%, and 55.53% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of TRACON Pharmaceuticals Inc (NASDAQ: TCON) shares accounts for 11.23% of the company’s 44.27M shares outstanding.
It has a market capitalization of $17.74M and a beta (3y monthly) value of 0.76. The earnings-per-share (ttm) stands at -$0.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 22.02% over the week and 11.62% over the month.
Analysts forecast that TRACON Pharmaceuticals Inc (TCON) will achieve an EPS of -$0.06 for the current quarter, -$0.05 for the next quarter and -$0.25 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.36 a year ago. Earnings per share for the fiscal year are expected to decrease by -215.15%, and 28.85% over the next financial year.
Looking at the support for the TCON, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on April 16, 2021, with the firm’s price target at $14. Maxim Group coverage for the TRACON Pharmaceuticals Inc (TCON) stock in a research note released on February 10, 2021 offered a Buy rating with a price target of $24. H.C. Wainwright was of a view on December 23, 2019 that the stock is Buy, while Needham gave the stock Buy rating on March 01, 2019, issuing a price target of $7. Stifel on their part issued Buy rating on June 13, 2017.
